These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529 [TBL] [Abstract][Full Text] [Related]
17. The assembly and evaluation of antisense oligonucleotides applied in exon skipping for titin-based mutations in dilated cardiomyopathy. Hahn JK; Neupane B; Pradhan K; Zhou Q; Testa L; Pelzl L; Maleck C; Gawaz M; Gramlich M J Mol Cell Cardiol; 2019 Jun; 131():12-19. PubMed ID: 30998980 [TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for Congenital Myasthenic Syndromes. Tei S; Ishii HT; Mitsuhashi H; Ishiura S Biochem Biophys Res Commun; 2015 Jun; 461(3):481-6. PubMed ID: 25888793 [TBL] [Abstract][Full Text] [Related]
19. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy. Goyenvalle A; Babbs A; van Ommen GJ; Garcia L; Davies KE Mol Ther; 2009 Jul; 17(7):1234-40. PubMed ID: 19455105 [TBL] [Abstract][Full Text] [Related]
20. A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene. Pramono ZA; Wee KB; Wang JL; Chen YJ; Xiong QB; Lai PS; Yee WC Hum Gene Ther; 2012 Jul; 23(7):781-90. PubMed ID: 22486275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]